BioResponse
Manufacturer and originator of a microencapsulated diindolylmethane (DIM) ingredient and supplements. The company develops and licenses a microencapsulation delivery technology for oral DIM, supports clinical research on estrogen metabolism, holds related patents, supplies ingredient powder to manufacturers, and sells finished dietary supplement products direct-to-consumer and through wholesale channels.
Industries
Nr. of Employees
small (1-50)
Patents
Products
BioResponse DIM 150
Dietary supplement capsule containing 150 mg of microencapsulated diindolylmethane (DIM) per capsule; 60 capsules per bottle.
BioResponse DIM 75
Dietary supplement capsule containing 75 mg of microencapsulated diindolylmethane (DIM) per capsule.
DIM Palmetto
Finished dietary supplement product combining DIM with other ingredients, supplied as softgels.
DIM Enhanced
Finished dietary supplement product formulated with microencapsulated DIM, provided as vegetarian capsules.
BioResponse DIM 150
Dietary supplement capsule containing 150 mg of microencapsulated diindolylmethane (DIM) per capsule; 60 capsules per bottle.
BioResponse DIM 75
Dietary supplement capsule containing 75 mg of microencapsulated diindolylmethane (DIM) per capsule.
DIM Palmetto
Finished dietary supplement product combining DIM with other ingredients, supplied as softgels.
DIM Enhanced
Finished dietary supplement product formulated with microencapsulated DIM, provided as vegetarian capsules.
Services
Supply of microencapsulated active-ingredient powder and licensing of formulation technology to manufacturers and brands worldwide.
Wholesale pricing and private-label product options for health practitioners, pharmacies, and retailers via a wholesale group membership.
Supply of microencapsulated active-ingredient powder and licensing of formulation technology to manufacturers and brands worldwide.
Wholesale pricing and private-label product options for health practitioners, pharmacies, and retailers via a wholesale group membership.
Expertise Areas
- Formulation development for enhanced oral bioavailability
- Microencapsulation delivery systems
- Clinical pharmacokinetics and bioavailability assessment
- Clinical trial collaboration and biomarker studies
Key Technologies
- Microencapsulation delivery systems
- Extended-release oral formulation
- Pharmacokinetic/bioavailability assays (blood sampling)
- Accelerated and real-time stability testing
News & Updates
Conference presentation on hormonal balance and DIM by company leadership.
Presentation on microencapsulated diindolylmethane formulation performance at a Controlled Release Society meeting.
Reference to a review and published abstract noting that indole-3-carbinol converts to DIM in vivo and that DIM is the active compound.
More than 15 published clinical studies have used the company's microencapsulated DIM formulation demonstrating bioavailability, safety, and tolerability.
Holder of numerous U.S. and international patents covering formulation technology and methods of use for diindolylmethane.
Conference presentation on hormonal balance and DIM by company leadership.
Presentation on microencapsulated diindolylmethane formulation performance at a Controlled Release Society meeting.
Reference to a review and published abstract noting that indole-3-carbinol converts to DIM in vivo and that DIM is the active compound.
More than 15 published clinical studies have used the company's microencapsulated DIM formulation demonstrating bioavailability, safety, and tolerability.
Holder of numerous U.S. and international patents covering formulation technology and methods of use for diindolylmethane.